Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 7673782

Metabolic screening.

T F Thurmon
View original source ↗Export metadata ↓

Abstract

The time-honored concept of utilization of the laboratory for screening for metabolic diseases has taken on new meaning in the face of the extensive heterogeneity of genetic diseases that has been revealed by DNA research. Some of the conditions for which screening was used in the past are now known to produce physically identifiable features so more definitive tests may be utilized for them. There remains a set of diseases that are difficult to characterize physically and it is for these that screening tests are most needed. Initial screening procedures for most of them are available in most general hospitals but comprehensive screening is usually done in biochemical genetics laboratories. Numerous and somewhat arcane bedside screening tests have been replaced by a short list of more modern procedures which are much more accurate and reliable.

Explore related subjects

EpilepsyHumansInfant, NewbornIntellectual DisabilityMetabolism, Inborn ErrorsNeonatal ScreeningJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

T F Thurmon. 1995. Metabolic screening.. https://pubmed.ncbi.nlm.nih.gov/7673782/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2026

Long-term seizure outcomes and factors associated with response to adjunctive everolimus in TSC-associated epilepsy.

BACKGROUND: Everolimus, a mechanistic target of rapamycin (mTOR) inhibitor, is increasingly used in tuberous sclerosis complex (TSC)-associated epilepsy; however, long-term real-world outcomes and factors associated with favorable response remain unclear. This study aimed to evaluate the long-term seizure outcomes of adjunctive everolimus and explore clinical factors associated with treatment response. METHODS: We retrospectively recruited 21 patients with active TSC-associated epilepsy receiving adjunctive everolimus and assessed seizure outcomes during follow-up. Clinical characteristics were compared between responders and non-responders at 1 year after treatment initiation. RESULTS: Over a median treatment duration of 72 months, responder rates ranged from 53.8% to 64.7%, and seizure-free rates ranged from 33.3% to 41.2%. Responders had fewer involved organ systems at baseline (median 3 vs. 4, p = 0.020) and lower anti-seizure medication burden (median 2 vs. 4, p = 0.045). Younger age at treatment initiation showed a trend toward improved response. CONCLUSION: Adjunctive everolimus was associated with sustained long-term seizure reduction in this real-world cohort. In exploratory analyses, fewer involved organ systems and fewer baseline ASMs were associated with favorable treatment response. These findings require validation in larger prospective cohorts.

Epilepsy↗